Core Viewpoint - The company, HaiSiKe Pharmaceutical Group Co., Ltd., has responded to an inquiry regarding its application for a specific stock issuance, detailing its operational performance, R&D investment, and financial status, showcasing its development trends and strategic layout in the pharmaceutical sector [1] Financial Performance - HaiSiKe's operating revenue increased from 3,015.29 million yuan in 2022 to 3,721.35 million yuan in 2024, indicating a growth trend [1] - The main revenue contributor, the innovative drug Ropivacaine injection, saw its revenue rise from 434.59 million yuan in 2022 to 1,214.43 million yuan in 2024 [1] - Gross profit margins improved from 69.51% in 2022 to 72.96% in 2024, primarily due to increased sales of Ropivacaine injection [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 111.82 million yuan in 2022, 242.12 million yuan in 2023, and 132.20 million yuan in 2024, with the 2024 figure not aligning with revenue trends due to increased expenses and asset impairment losses [1] Product Analysis - The anesthetic product market is experiencing growth, with Ropivacaine injection expanding its market share [2] - The parenteral nutrition market is developing steadily, although related product revenues have declined [2] - The antiemetic market shows clear demand, with the company's Dexamethasone injection maintaining stable revenue [2] - Overall product prices remain stable, with some fluctuations due to national negotiations and centralized procurement, while sales volumes are generally on the rise [2] R&D and Financial Status - R&D investments for the reporting period were 960.86 million yuan, 875.43 million yuan, 1,000.94 million yuan, and 496.55 million yuan, with a high proportion of capitalized R&D expenditures compared to industry peers [2] - The company received significant government subsidies in 2023-2024, primarily from the Tibet Autonomous Region [2] - Accounts receivable turnover is below industry averages due to sales channel optimization, with a prolonged collection cycle but sufficient bad debt provisions [3] - The company’s dividend policy aligns with its profit levels, cash flow, and business scale, ensuring compliance with regulations and protecting minority investors' rights [3] Stock Issuance Plan - HaiSiKe plans to raise no more than 1,365.26 million yuan through a specific stock issuance, with 965.26 million yuan allocated for new drug R&D projects and 400 million yuan for working capital [4] - The new drug R&D projects involve six products that are already in clinical development, with manageable risks associated with potential R&D failures [4]

持续打造创新药"超级产业链"，医药企业海思科（002653）(002653.SZ)经营业绩向好。 近日，海思科发布2024年年度报告，报告期，公司实现营收37.21亿元，同比增长10.92%；实现净利润 3.95亿元，同比增长34%；拟全体股东每10股派发现金红利1.35元(含税)。 据了解，海思科以特色仿制药起家，现已转型为麻醉及镇痛、糖尿病及并发症、肿瘤、神经痛等领域的 创新药企。公司目前有40多个品种为国内首家或独家仿制，主要产品包括创新药环泊酚注射液、甲磺酸 多拉司琼注射液等。 长江商报记者注意到，作为国家级高新技术企业，海思科十分重视研发积累。2020年—2024年，公司研 发投入分别为7.09亿元、8.15亿元、9.58亿元、8.75亿元、10.01亿元，累计达43.58亿元。 持续的高投入也为公司创新药管线的稳步推进提供了坚实保障，截至目前，海思科的商业化产品及进入 临床阶段的1类新药共有14个。 创新药业务增长强劲 公开资料显示，海思科成立于2000年，是一家集新药研发、生产制造、销售等业务于一体的医药上市公 司。其研发中心的科研工作涉及肠外营养、肿瘤、心脑血管、抗病毒、内分泌、中枢神经等多个 ...